Author

Luisa Castro Laria 1

1 HU Virgen Macarena,Seville,Spain

Long-term follow-up of switching from original infliximab to infliximab biosimilar. Real world data

Maria Belvis Jiménez, Maria Fernanda Guerra Veloz, Belen Maldonado Pérez, Teresa Valdes-Delgado, Luisa Castro Laria, Raul Perea, Javier Calleja, Vicente Merino, Antonio Benítez Roldán, Ángel Caunedo Álvarez, Federico Argüelles-Arias

PREDICTORS OF VEDOLIZUMAB RESPONSE TO INDUCTION: REAL LIFE EXPERIENCE

Maria Inmaculada Belvis Jiménez, Ana Gutierrez Casbas, Juan Maria Vázquez Morón, Maríife García Sepulcro, Belen Maldonado Pérez, Laura Sempere Robles, Raquel Laveda Cano, Héctor Pallarés Manrique, Elena Gomez, Luisa Castro Laria, Federico Aargüelles Arias

Are cut-off ranges of Infliximab serum levels in Crohn´s disease always the same in clinical practice?

Teresa Valdes-Delgado, Maria Fernanda Guerra Veloz, Federico Argüelles-Arias, Belen Maldonado Pérez, Luisa Castro Laria, Ángel Caunedo-Álvarez

SWITCHING FROM REFERENCE INFLIXIMAB TO CT-P13 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 12 MONTHS RESULTS

Maria Fernanda Guerra Veloz, Federico Argüelles Arias,, Raul Perea Amarillo, Luisa Castro Laria, Belen Maldonado Pérez, Dina Chaaro, Antonio Benítez Roldán, Vicente Merino, Gabriel Ramirez, Ángel Caunedo Álvarez, Manuel Romero Gómez

PROGNOSIS OF PATIENTS WITH ULCERATIVE COLITIS IN SUSTAINED REMISSION AFTER THIOPURINES WITHDRAWAL

Estefanía Moreno Rincón, Jose Manuel Benitez, Francisco Javier Serrano Ruiz, Juan Maria Vázquez Morón, Héctor Pallarés Manrique, José Manuel Herrera Justiniano, Eduardo Leo Carnerero, María Rosario Gómez García, María José Cabello Tapia, Manuel Castro Fernández, María Rojas Feria, Luisa Castro Laria, Federico Argüelles Arias,

Item 1 - 5 / 5
1